Form 4: Director Lee Newcomer Receives Coherus Equity Grant
Statement of Changes in Beneficial Ownership
Coherus Oncology director Lee Nisley Newcomer was granted 30,000 restricted stock units and 60,000 stock options.
Summary
- Director Lee Nisley Newcomer acquired 30,000 restricted stock units (RSUs) on June 5, 2026.
- Director Newcomer was granted 60,000 stock options with an exercise price of $1.45 per share.
- The RSUs vest 100% on the one-year anniversary of June 3, 2026.
- The stock options vest and become exercisable 100% on June 3, 2027.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Long-term retention incentive created by the one-year vesting schedule.
Negatives
- Potential for future shareholder dilution upon the exercise of options and vesting of RSUs.
Risks
- Continued service requirement for vesting creates dependency on the director's ongoing relationship with the company.
- Market price volatility may impact the ultimate value of the equity grants.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on director equity compensation.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board alignment with long-term shareholder value creation.
Comparison to Industry Standards
- The use of RSUs and stock options is consistent with standard compensation packages for non-employee directors in mid-cap biotech firms.
- The one-year cliff vesting period is a common industry practice for director equity awards.
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise of these options and vesting of RSUs.
Next Steps
- Vesting of RSUs on June 3, 2027.
- Vesting of stock options on June 3, 2027.
Key Dates
| Date | Description |
|---|---|
| 06/03/2026 | Vesting commencement date for RSUs and options. |
| 06/05/2026 | Date of grant for RSUs and stock options. |
| 06/09/2026 | Filing date of the Form 4. |
| 06/03/2027 | Vesting date for RSUs and options. |
| 06/05/2036 | Expiration date for stock options. |
Keywords
Coherus Oncology, CHRS, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.